Immunotherapy in the era of transplant oncology: Risks and complications DOI

Bilal Anouti,

Reham Abdel‐Wahab, Adi Diab

et al.

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 135 - 147

Published: Nov. 15, 2024

Language: Английский

An Updated Review of Immune Checkpoint Inhibitors in Cutaneous Oncology: Beyond Melanoma DOI Creative Commons
James P. Pham, Ramon Staeger, Anthony M. Joshua

et al.

European Journal of Cancer, Journal Year: 2024, Volume and Issue: 214, P. 115121 - 115121

Published: Nov. 16, 2024

Language: Английский

Citations

3
Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec DOI Creative Commons

Jamie Lebhar,

Jennifer Jacobs, Khushnood Faraz

et al.

JAAD Case Reports, Journal Year: 2023, Volume and Issue: 40, P. 53 - 57

Published: Aug. 9, 2023

Language: Английский

Citations

4
Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies DOI Creative Commons
Stephanie Ji, Hao Liu,

Laura A. Pachella

et al.

Frontiers in Transplantation, Journal Year: 2023, Volume and Issue: 2

Published: Oct. 30, 2023

Background Immune checkpoint inhibitors (ICI) are standard of care therapy for patients with cutaneous malignancies, the most frequently diagnosed cancers in solid organ transplant (SOT) recipients. The activity and rate allograft rejection SOT recipients advanced skin treated ICI is understudied. Methods We conducted a retrospective analysis melanoma, squamous cell carcinoma (cSCC), merkel (MCC) who were ICI. Unpublished cases from our institution published literature aggregated. Demographics, type immunosuppressive therapy, ICI(s) administered, prior systemic therapies, tumor response to ICI, evidence and/or failure recorded. Objective rates (ORR) graft reported. Results Ninety identified; four 86 unique review. ORR first-line entire cohort was 41.1% (37/90). by 31% (18/58), 64.3% (18/28), 25.0% (1/4) cSCC, MCC, respectively. 37.8% (34/90) 61.8% (21/34) these progressing failure. Number agents (0, 1, 2, or 3) inversely associated Conclusions In this analysis, ICIs demonstrate clinical malignancies; however, high. Treatment plans should be individualized through thorough interdisciplinary discussion. Immunosuppressive modifications may considered starting treatment, but when feasible, enrollment on trials preferred.

Language: Английский

Citations

4
Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances DOI Creative Commons

Spencer Lessans,

Katie A. O’Connell, Jennifer H. Choe

et al.

Current Oncology Reports, Journal Year: 2024, Volume and Issue: 26(9), P. 1120 - 1133

Published: July 2, 2024

This review provides an update on approved and emerging systemic therapies in the treatment of locally advanced or metastatic non-melanoma skin cancers (squamous cell carcinoma, basal Merkel carcinoma).

Language: Английский

Citations

1
Current Advances and Challenges in the Management of Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients DOI Open Access
Sophie H. Li,

Thomas Townes,

Shorook Na’ara

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(18), P. 3118 - 3118

Published: Sept. 10, 2024

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin malignancy and poses a significant risk to immunosuppressed patients, such as solid organ transplant recipients those with hematopoietic malignancies, who are up 100 times more likely develop cSCC compared general population. This review summarizes current state of treatment for in focusing on prevention, prophylaxis, surgical non-surgical treatments, emerging therapies. Preventative measures, including high-SPF sunscreen prophylactic retinoids, crucial reducing incidence these patients. Adjusting immunosuppressive regimens, particularly favoring mTOR inhibitors over calcineurin inhibitors, has been shown lower risk. Surgical excision Mohs micrographic surgery remain primary adjuvant radiation therapy recommended high-risk cases. Traditional chemotherapy targeted therapies like EGFR have utilized, though their efficacy varies. Immunotherapy, agents cemiplimab pembrolizumab, promise, but its use patients requires further investigation due potential risks rejection exacerbation underlying conditions. Treatment multifaceted, involving preventive strategies, tailored approaches, cautious systemic While immunotherapy emerged promising option, application populations necessitates research optimize safety efficacy. Future studies should focus integration personalized medicine combination improve outcomes this vulnerable patient group.

Language: Английский

Citations

1
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Nephrotoxicity: A Position Statement from the American Society of Onco-nephrology DOI
Sandra M. Herrmann, Ala Abudayyeh, Shruti Gupta

et al.

Kidney International, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

Citations

1
Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer DOI Creative Commons
Eric S. Christenson,

Valerie Lee,

Hao Wang

et al.

Current Oncology, Journal Year: 2022, Volume and Issue: 30(1), P. 75 - 84

Published: Dec. 21, 2022

Solid organ transplants are associated with a modestly increased risk of colorectal cancers (CRC). However, the molecular profile these has not been described. We hypothesized that transplant-related immunosuppression may promote development more immunogenic tumors as suggested by high tumor mutation burden or mismatch repair deficiency. performed an electronic medical record search for patients seen in Johns Hopkins University Health System (JHHS) between 2017 and 2022 who developed CRC following solid transplantation. A comparator cohort treated at JHHS profiling data was also identified. In this case, 29 were identified post-transplant (renal transplant, n = 18; liver 8; kidney-liver transplantation, 3). Compared to general population cohort, had higher rate deficiency (41% versus 12%, p-value 0.0038), elevated (median 22 mut/Mb 3.5 mut/Mb, 0.033) (range 3.52–53.65). Post-transplant enriched PIK3CA mutations (43% 24%, 0.042). Post-Transplant CRCs clinical features immune sensitivity, supporting potential role impaired surveillance shaping landscape CRCs. These results help inform management CRC.

Language: Английский

Citations

3
Checkpoint Inhibition for Kidney Transplant Recipients With Advanced Cutaneous Carcinomas: An Emerging Standard for Select Patients DOI
Shlomo A. Koyfman, J.L. Geiger

Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 42(9), P. 981 - 983

Published: Feb. 8, 2024

Language: Английский

Citations

0
Multiple Options: How to Choose Therapy in Frontline Metastatic Melanoma DOI
Lucy Boyce Kennedy, April K.S. Salama

Current Oncology Reports, Journal Year: 2024, Volume and Issue: unknown

Published: June 5, 2024

Language: Английский

Citations

0
Immunotherapy for Advanced Skin Cancer in Kidney Transplant Recipients—The High-Risk Balancing Act DOI
Madeliene Stump, Sarah T. Arron, Charlotte M. Proby

et al.

JAMA Dermatology, Journal Year: 2024, Volume and Issue: 160(8), P. 799 - 799

Published: Aug. 1, 2024

This Viewpoint compares 2 clinical trials involving immune checkpoint inhibitors in kidney transplant recipients.

Language: Английский

Citations

0